FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296072> ?p ?o ?g. }

• W4367296072 abstract "<h3>Objective:</h3> Describe experience with use of efgartigimod in clinical practice in the first year after FDA approval. <h3>Background:</h3> Efgartigimod is a first-in-class neonatal Fc receptor (FcRn) antagonist approved for treatment of acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ gMG). In the pivotal trial, patients received an initial 4-infusion treatment cycle with subsequent treatment cycles occurring based on loss of treatment response or a minimum of 5 weeks from last infusion. <h3>Design/Methods:</h3> Retrospective chart review. Patients with AchR+ gMG who were treated with efgartigimod and for whom myasthenia gravis activities of daily living (MG-ADL) scores were available prior to as well as after completion of treatment cycle were included in the cohort. Patients from three major academic neuromuscular centers were included. Information regarding MG history, MG treatment(s) immediately prior to efgartigimod start, MG-ADL and other MG-specific outcome measures, laboratory data and adverse events were recorded. <h3>Results:</h3> Of 20 patients who received the first cycle of efgartigimod, 11 were male and 9 were female with mean age of 61.35 (+18.03) year. 14 patients (70%) had clinically meaningful improvement (> 2 points) in MG-ADL scores, whereas 3 each had no change and worsening respectively. Total IGG levels decreased by mean of 61% (± 17%) in the 8 patients for whom data was available. To date, over 20 patients have received at least 1 cycle of efgartigimod and of these patients, 11 have received 2 or more cycles. <h3>Conclusions:</h3> Our experience suggests that at least two third of the patients with AChR+ gMG have clinically meaningful improvement in MG-ADL scores after first treatment cycle of efgartigimod. Clinical response to subsequent treatment cycles and new initiations will be discussed. <b>Disclosure:</b> Dr. Katyal has nothing to disclose. Dr. Halldorsdottir has nothing to disclose. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. An immediate family member of Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care. Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for argenx. Dr. Muppidi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB/Ra Pharma. Dr. Muppidi has received publishing royalties from a publication relating to health care. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH/NINDS. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for argenx. The institution of Dr. Habib has received research support from Alexion. The institution of Dr. Habib has received research support from RA pharmaceuticals. The institution of Dr. Habib has received research support from Immunovant. The institution of Dr. Habib has received research support from UCB. The institution of Dr. Habib has received research support from argenx. The institution of Dr. Habib has received research support from CabalettaBio. The institution of Dr. Habib has received research support from Genentech. The institution of Dr. Habib has received research support from Regeneron." @default.
• W4367296072 created "2023-04-29" @default.
• W4367296072 creator A5004702963 @default.
• W4367296072 creator A5009958786 @default.
• W4367296072 creator A5015588515 @default.
• W4367296072 creator A5016703264 @default.
• W4367296072 creator A5055638914 @default.
• W4367296072 creator A5068289916 @default.
• W4367296072 date "2023-04-25" @default.
• W4367296072 modified "2023-09-29" @default.
• W4367296072 title "Clinical Experience With Efgartigimod For Treatment Of Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis (P1-8.004)" @default.
• W4367296072 doi "https://doi.org/10.1212/wnl.0000000000202807" @default.
• W4367296072 hasPublicationYear "2023" @default.
• W4367296072 type Work @default.
• W4367296072 citedByCount "0" @default.
• W4367296072 crossrefType "proceedings-article" @default.
• W4367296072 hasAuthorship W4367296072A5004702963 @default.
• W4367296072 hasAuthorship W4367296072A5009958786 @default.
• W4367296072 hasAuthorship W4367296072A5015588515 @default.
• W4367296072 hasAuthorship W4367296072A5016703264 @default.
• W4367296072 hasAuthorship W4367296072A5055638914 @default.
• W4367296072 hasAuthorship W4367296072A5068289916 @default.
• W4367296072 hasConcept C126322002 @default.
• W4367296072 hasConcept C167135981 @default.
• W4367296072 hasConcept C170493617 @default.
• W4367296072 hasConcept C187212893 @default.
• W4367296072 hasConcept C197934379 @default.
• W4367296072 hasConcept C2778105408 @default.
• W4367296072 hasConcept C3020341438 @default.
• W4367296072 hasConcept C71924100 @default.
• W4367296072 hasConcept C72563966 @default.
• W4367296072 hasConcept C80161118 @default.
• W4367296072 hasConceptScore W4367296072C126322002 @default.
• W4367296072 hasConceptScore W4367296072C167135981 @default.
• W4367296072 hasConceptScore W4367296072C170493617 @default.
• W4367296072 hasConceptScore W4367296072C187212893 @default.
• W4367296072 hasConceptScore W4367296072C197934379 @default.
• W4367296072 hasConceptScore W4367296072C2778105408 @default.
• W4367296072 hasConceptScore W4367296072C3020341438 @default.
• W4367296072 hasConceptScore W4367296072C71924100 @default.
• W4367296072 hasConceptScore W4367296072C72563966 @default.
• W4367296072 hasConceptScore W4367296072C80161118 @default.
• W4367296072 hasLocation W43672960721 @default.
• W4367296072 hasOpenAccess W4367296072 @default.
• W4367296072 hasPrimaryLocation W43672960721 @default.
• W4367296072 hasRelatedWork W1953864717 @default.
• W4367296072 hasRelatedWork W197760010 @default.
• W4367296072 hasRelatedWork W1984843671 @default.
• W4367296072 hasRelatedWork W1996646445 @default.
• W4367296072 hasRelatedWork W1999552103 @default.
• W4367296072 hasRelatedWork W2039154000 @default.
• W4367296072 hasRelatedWork W2078654174 @default.
• W4367296072 hasRelatedWork W2083022333 @default.
• W4367296072 hasRelatedWork W2416599176 @default.
• W4367296072 hasRelatedWork W4233150862 @default.
• W4367296072 isParatext "false" @default.
• W4367296072 isRetracted "false" @default.
• W4367296072 workType "article" @default.